182 related articles for article (PubMed ID: 31786872)
1. Neoadjuvant chemotherapy combined with interval cytoreductive surgery in ovarian cancer.
Li X; Du X
J BUON; 2019; 24(5):2035-2040. PubMed ID: 31786872
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.
Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC
Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454
[TBL] [Abstract][Full Text] [Related]
3. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
[TBL] [Abstract][Full Text] [Related]
4. Platinum-Based Neoadjuvant Chemotherapy versus Primary Surgery in Ovarian Carcinoma International Federation of Gynecology and Obstetrics Stages IIIc and IV: A Systematic Review and Meta-Analysis.
Xiao Y; Xie S; Zhang N; Wang J; Lv C; Guo J; Yang Q
Gynecol Obstet Invest; 2018; 83(3):209-219. PubMed ID: 29402804
[TBL] [Abstract][Full Text] [Related]
5. Impact of increased utilization of neoadjuvant chemotherapy on survival in patients with advanced ovarian cancer: experience from a comprehensive cancer center.
Lee YJ; Chung YS; Lee JY; Nam EJ; Kim SW; Kim S; Kim YT
J Gynecol Oncol; 2018 Jul; 29(4):e63. PubMed ID: 29770632
[TBL] [Abstract][Full Text] [Related]
6. Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy.
Lyons YA; Reyes HD; McDonald ME; Newtson A; Devor E; Bender DP; Goodheart MJ; Gonzalez Bosquet J
Int J Gynecol Cancer; 2020 Jun; 30(6):845-852. PubMed ID: 32341114
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma.
Kuhn W; Rutke S; Späthe K; Schmalfeldt B; Florack G; von Hundelshausen B; Pachyn D; Ulm K; Graeff H
Cancer; 2001 Nov; 92(10):2585-91. PubMed ID: 11745193
[TBL] [Abstract][Full Text] [Related]
8. Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients.
Zhang J; Liu N; Zhang A; Bao X
J Obstet Gynaecol Res; 2018 Sep; 44(9):1808-1816. PubMed ID: 30019801
[TBL] [Abstract][Full Text] [Related]
9. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
[TBL] [Abstract][Full Text] [Related]
10. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
[TBL] [Abstract][Full Text] [Related]
11. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
Bian C; Yao K; Li L; Yi T; Zhao X
Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168
[TBL] [Abstract][Full Text] [Related]
12. Application of combined intraperitoneal and intravenous neoadjuvant chemotherapy in senile patients with advanced ovarian cancer and massive ascites.
Liu EL; Mi RR; Wang DH; Wang LQ; Zhang YM; Chen WM
Eur J Gynaecol Oncol; 2017; 38(2):209-213. PubMed ID: 29953782
[TBL] [Abstract][Full Text] [Related]
13. Impact of prehabilitation during neoadjuvant chemotherapy and interval cytoreductive surgery on ovarian cancer patients: a pilot study.
Miralpeix E; Sole-Sedeno JM; Rodriguez-Cosmen C; Taus A; Muns MD; Fabregó B; Mancebo G
World J Surg Oncol; 2022 Feb; 20(1):46. PubMed ID: 35197061
[TBL] [Abstract][Full Text] [Related]
14. [Impact of neoadjuvant chemotherapy on the survival of patients with stage IIIc and IV epithelial ovarian cancer].
Yan X; An N; Jiang GQ; Gao M; Gao YN
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):298-301. PubMed ID: 18788637
[TBL] [Abstract][Full Text] [Related]
15. Role of neoadjuvant chemotherapy in the management of advanced ovarian cancer.
Zhao D; Wu LY; Wang XB; Li XG
Asian Pac J Cancer Prev; 2015; 16(6):2369-73. PubMed ID: 25824766
[TBL] [Abstract][Full Text] [Related]
16. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
Chang SJ; Bristow RE; Ryu HS
Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
[TBL] [Abstract][Full Text] [Related]
17. An international worldwide retrospective cohort observational study comparing primary cytoreductive surgery with neoadjuvant chemotherapy and interval cytoreductive surgery in patients with carcinoma of the ovary, fallopian tubes, and peritoneum (SUROVA trial).
Chiva L; Ordás P; Martin-Calvo N; Aramendia JM; Sanchez Lorenzo L; Gallego Martínez A; Vizcay Á; Minguez JA; Manzour N; Vázquez-Vicente D; Chacon E; Castellanos T; Gonzalez Martin A
Int J Gynecol Cancer; 2024 Jun; 34(6):942-945. PubMed ID: 38479803
[TBL] [Abstract][Full Text] [Related]
18. Oncologic Concerns regarding Laparoscopic Cytoreductive Surgery in Patients with Advanced Ovarian Cancer Submitted to Neoadjuvant Chemotherapy.
Favero G; Macerox N; Pfiffer T; Köhler C; da Costa Miranda V; Estevez Diz Mdel P; Fukushima JT; Baracat EC; Carvalho JP
Oncology; 2015; 89(3):159-66. PubMed ID: 25968072
[TBL] [Abstract][Full Text] [Related]
19. BRCA1-associated and sporadic ovarian carcinomas: outcomes of primary cytoreductive surgery or neoadjuvant chemotherapy.
Gorodnova T; Sokolenko A; Ni V; Ivantsov A; Kotiv K; Petrik S; Amelina I; Berlev I; Imyanitov E
Int J Gynecol Cancer; 2019 May; 29(4):779-786. PubMed ID: 30839285
[TBL] [Abstract][Full Text] [Related]
20. Does neoadjuvant chemotherapy plus cytoreductive surgery improve survival rates in patients with advanced epithelial ovarian cancer compared with cytoreductive surgery alone?
Solmaz U; Mat E; Dereli ML; Turan V; Peker N; Tosun G; Dogan A; Adiyeke M; Ozdemir A; Gungorduk K; Sanci M; Yildirim Y
J BUON; 2015; 20(3):847-54. PubMed ID: 26214639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
